Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis

References

• Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47(17):2493–511.
   PubMed Web of Science ®Google Scholar
• Delaney TF, Yang JC, Glatstein E. Adjuvant therapy for adult patients with soft tissue sarcomas. Oncology (Williston Park). 1991; 5(105–118): 123–04. discussion 118, 120, :
   Google Scholar
• Gronchi A, Miceli R, Colombo C, Collini P, Stacchiotti S, Olmi P, Mariani L, Bertulli R, Fiore M, Casali PG, et al. Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. Ann Oncol. 2011;22(7):1675–81.
   PubMed Web of Science ®Google Scholar
• Blay J-Y, van Glabbeke M, Verweij J, van Oosterom AT, Le Cesne A, Oosterhuis JW, Judson I, Nielsen OS. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer. 2003;39(1):64–9.
   PubMed Web of Science ®Google Scholar
• Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008;112(7):1585–91.
   PubMed Web of Science ®Google Scholar
• Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007; 370:2020–9.
   PubMed Web of Science ®Google Scholar
• Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. International Adjuvant Lung Cancer Trial Collaborative G. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350:351–60.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Loibl S. Evolution of adjuvant chemotherapy for breast cancer. Lancet. 2015;385(9980):1812–4.
   PubMed Web of Science ®Google Scholar
• Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.
   PubMed Web of Science ®Google Scholar
• Collaboration SM-a. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997; 350:1647–54.
   PubMed Web of Science ®Google Scholar
• Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PCW, EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54.
   PubMed Web of Science ®Google Scholar
• Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol. 2013;24(4):1099–104.
   PubMed Web of Science ®Google Scholar
• Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Ueno NT. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2015;1(9):1311–8.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, Group P, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med. 1998;17(24):2815–34.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12:9
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG. Assessing risk of bias in included studies. UK: John Wiley & Sons; 2008.
   Google Scholar
• Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics. 1998;7(4):434–55.
   Web of Science ®Google Scholar
• Malouf GG, Duclos J, Rey A, Duvillard P, Lazar V, Haie-Meder C, Balleyguier C, Morice P, Lhommé C, Pautier P, et al. Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma. Ann Oncol. 2010;21(10):2102–6.
   PubMed Web of Science ®Google Scholar
• Italiano A, Penel N, Robin Y-M, Bui B, Le Cesne A, Piperno-Neumann S, Tubiana-Hulin M, Bompas E, Chevreau C, Isambert N, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol. 2009;20(3):425–30.
   PubMed Web of Science ®Google Scholar
• Schenone AD, Luo J, Montgomery L, Morgensztern D, Adkins DR, Van Tine BA. Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy. Cancer Med. 2014;3(3):603–12.
   PubMed Web of Science ®Google Scholar
• Grobmyer SR, Maki RG, Demetri GD, Mazumdar M, Riedel E, Brennan MF, Singer S. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004;15(11):1667–72.
   PubMed Web of Science ®Google Scholar
• Nevala R, Tukiainen E, Tarkkanen M, Bohling T, Blomqvist C, Sampo M. (Neo)adjuvant chemotherapy and interdigitated split-course hyperfractionated radiation in high risk soft tissue sarcoma - Results from a large single-institution series. Sci Rep. 2019;9(1):7304
   PubMedGoogle Scholar
• Chen Y, Yang Y, Wang C, Shi Y. Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients. J Surg Oncol. 2012;106(2):162–8.
   PubMed Web of Science ®Google Scholar
• Kasper B, Ouali M, van Glabbeke M, Blay J-Y, Bramwell VHC, Woll PJ, Hohenberger P, Schöffski P. Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931. Eur J Cancer. 2013;49(2):449–56.
   PubMed Web of Science ®Google Scholar
• Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, Beecham J, Park R, Silverberg S. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985;3(9):1240–5.
   PubMed Web of Science ®Google Scholar
• Antman K, Suit H, Amato D, Corson J, Wood W, Proppe K, Harmon D, Carey R, Greenberger J, Blum R, et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. J Clin Oncol. 1984;2(6):601–8.
   PubMed Web of Science ®Google Scholar
• Lerner HJ, Amato DA, Savlov ED, DeWys WD, Mittleman A, Urtasun RC, Sobel S, Shiraki M. Eastern Cooperative Oncology Group: a comparison of adjuvant doxorubicin and observation for patients with localized soft tissue sarcoma. J Clin Oncol. 1987;5(4):613–7.
   PubMed Web of Science ®Google Scholar
• Alvegård TA, Sigurdsson H, Mouridsen H, Solheim O, Unsgaard B, Ringborg U, Dahl O, Nordentoft AM, Blomqvist C, Rydholm A, et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol. 1989;7(10):1504–13.
   PubMed Web of Science ®Google Scholar
• Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, Ruka W, Priario J, Wagener T, Burgers M, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12(6):1137–49.
   PubMed Web of Science ®Google Scholar
• Glenn J, Kinsella T, Glatstein E, Tepper J, Baker A, Sugarbaker P, Sindelar W, Roth J, Brennan M, Costa J, et al. A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. Cancer. 1985;55(6):1206–14.
   PubMed Web of Science ®Google Scholar
• Glenn J, Sindelar WF, Kinsella T, Glatstein E, Tepper J, Costa J, Baker A, Sugarbaker P, Brennan MF, Seipp C, et al. Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum. Surgery. 1985;97(3):316–25.
   PubMed Web of Science ®Google Scholar
• Antman K, Ryan L, Borden E. Pooled results from three randomized adjuvant studies of doxoru bicin versus observation in soft tissue sarcoma: 10 year results and review of the literature. In: Salmon SE, editor. Adjuvant therapy of cancer VI. Philadelphia: WB Saunders; 1990. p. 529–43.
   Google Scholar
• Ravaud A, Bui NB, Coindre JM. Adjuvant chemotherapy with cyvadic in high risk soft tissue sarcoma: a randomized prospective trial. In: Salmon SE, editor. Adjuvant therapy of cancer VI. Philadelphia: WB Saunders; 1990. p. 556–66.
   Google Scholar
• Davis EJ, Chugh R, Zhao L, Lucas DR, Biermann JS, Zalupski MM, Feng M, Wong SL, Jacobson J, Zyczynski L, et al. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. Eur J Cancer. 2015;51(13):1794–802.
   PubMed Web of Science ®Google Scholar
• Gupta AM, Goel M, Sahay A, Janjal SP, Patkar S. Role of Adjuvant Chemotherapy in Extranodal Follicular Dendritic Cell Sarcoma. ACG Case Rep J. 2019;6(3):1–4.
   PubMed Web of Science ®Google Scholar
• Gherlinzoni F, Bacci G, Picci P, Capanna R, Calderoni P, Lorenzi EG, Bernini M, Emiliani E, Barbieri E, Normand A, et al. A Randomized Trial for the Treatment of High-Grade Soft-Tissue Sarcomas of the Extremities: Preliminary Observations. J Clin Oncol. 1986;4(4):552–8.
   PubMed Web of Science ®Google Scholar
• Brodowicz T, Schwameis E, Widder J, Amann G, Wiltschke C, Dominkus M, Windhager R, Ritschl P, Pötter R, Kotz R, et al. Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial. Sarcoma. 2000;4(4):151–60.
   PubMedGoogle Scholar
• Petrioli R, Coratti A, Correale P, D'Aniello C, Grimaldi L, Tanzini G, et al. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol. 2002; 25:468–73.
   PubMed Web of Science ®Google Scholar
• Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.
   PubMed Web of Science ®Google Scholar
• Gortzak E, Azzarelli A, Buesa J, Bramwell VHC, van Coevorden F, van Geel AN, Ezzat A, Santoro A, Oosterhuis JW, van Glabbeke M, et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096–103.
   PubMed Web of Science ®Google Scholar
• Edmonson JH. Systemic chemotherapy following complete excision of nonosseous sarcomas: Mayo Clinic experience. Cancer Treat Symp. 1985;3:89–97.
   Google Scholar
• Rosenberg SA, Tepper J, Glatstein E, Costa J, Young R, Baker A, Brennan MF, Demoss EV, Seipp C, Sindelar WF, et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer. 1983;52(3):424–34.
   PubMed Web of Science ®Google Scholar
• Chang AE, Kinsella T, Glatstein E, Baker AR, Sindelar WF, Lotze MT, Danforth DN, Sugarbaker PH, Lack EE, Steinberg SM, et al. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol. 1988;6(9):1491–500.
   PubMed Web of Science ®Google Scholar
• Benjamin RS, Terjanian TO, Fenoglio CJ. The importance of combination chemotherapy for adjuvant treatment of high-risk patients with soft-tissue sarcomas of the extremities. In:Salmon SE, editor. Adjuvant therapy of cancer V. Orlando: Grune and Stratton; 1987. p. 735–44.
   Google Scholar
• Radaelli S, Stacchiotti S, Casali PG, Gronchi A. Emerging therapies for adult soft tissue sarcoma. Expert Rev Anticancer Ther. 2014;14(6):689–704.
   PubMed Web of Science ®Google Scholar
• Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D, Duffaud F, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol. 2017;56(1):88–92.
   PubMed Web of Science ®Google Scholar
• Palmerini E, Staals EL, Alberghini M, Zanella L, Ferrari C, Benassi MS, Picci P, Mercuri M, Bacci G, Ferrari S, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer. 2009;115(13):2988–98.
   PubMed Web of Science ®Google Scholar
• Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101(3):627–34.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay J-Y, Tendero O, Beveridge RD, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812–22.
   PubMed Web of Science ®Google Scholar